Slide 1: AbbVie Reports First-Quarter 2025 Financial Results
PRESS RELEASE AbbVie Reports First-Quarter 2025 Financial Results • Reports First-Quarter Diluted EPS of $0.72 on a GAAP Basis, a Decrease of 6.5 Percent; Adjusted Diluted EPS of $2.46, an Increase of 6.5 Percent; These Results Include an Unfavorable Impact of $0.13 Per Share Related to Acquired IPR
Slide 2: First-Quarter Results
First-Quarter Results • Worldwide net revenues were $13.343 billion, an increase of 8.4 percent on a reported basis, or 9.8 percent on an operational basis. • Global net revenues from the immunology portfolio were $6.264 billion, an increase of 16.6 percent on a reported basis, or 18.1 percent on an
Slide 3: Recent Events
Recent Events • AbbVie announced that its board of directors unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman of the board of directors, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO a
Slide 4: Full-Year 2025 Outlook
Full-Year 2025 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2025 from $11.99 - $12.19 to $12.09 - $12.29, which includes an unfavorable impact of $0.13 per share related to acquired IPR&D and milestones expense incurred year-to-date through the first quarter 2025. Th
Slide 5: Forward-Looking Statements
Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional
Slide 6: Key Product Revenues Quarter Ended March 31, 2025
AbbVie Inc. Key Product Revenues Quarter Ended March 31, 2025 (Unaudited) % Change vs. 1Q24 Net Revenues (in millions) Reported Operationala U.S. Int’l. Total U.S. Int’l. Total Int’l. Total NET REVENUES $9,979 $3,364 $13,343 10.4% 2.9% 8.4% 8.3% 9.8% Immunology 4,883 1,381 6,264 17.6 13.4 16.6 20.1
Slide 7: Consolidated Statements of Earnings
AbbVie Inc. Consolidated Statements of Earnings (Unaudited) First Quarter (in millions, except per share data) Ended March 31 2025 2024 Net revenues $ 13,343 $ 12,310 Cost of products sold 4,002 4,094 Selling, general and administrative 3,293 3,315 Research and development 2,067 1,939 Acquired IPR&D
Slide 8: Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) 1. Specified items impacted results as follows: Quarter Ended March 31, 2025 (in millions, except per share data) Earnings Diluted Pre-tax After-taxa EPS As reported (GAAP) $ 1,661 $ 1,286 $ 0.72 Adjusted for sp
Slide 9: Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
AbbVie Inc. Reconciliation of GAAP Reported to Non-GAAP Adjusted Information (Unaudited) 1. Specified items impacted results as follows: Quarter Ended March 31, 2024 (in millions, except per share data) Earnings Diluted Pre-tax After-taxa EPS As reported (GAAP) $ 1,755 $ 1,369 $ 0.77 Adjusted for sp